MUC1 immunotherapy is here to stay

Cytotoxic T-lymphocyte Immunotherapy for Ovarian Cancer

(2012) Stephen E. Wright et al.   JOURNAL OF IMMUNOTHERAPY

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer

(2011) N. K. Ibrahim et al.   CLINICAL CANCER RESEARCH

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

(2011) S. A. Gulec et al.   CLINICAL CANCER RESEARCH

MUC1 Protein Expression in Tumor Cells Regulates Transcription of Proinflammatory Cytokines by Forming a Complex with Nuclear Factor-κB p65 and Binding to Cytokine Promoters

(2011) Sandra Cascio et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

(2011) Charles Butts et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

(2011) Elisabeth Quoix et al.   LANCET ONCOLOGY

Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies

(2010) S. P. Pinheiro et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

(2010) Stéphane Oudard et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909

(2010) Jürgen Kuball et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer

(2010) Charles Butts et al.   Clinical Lung Cancer

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

(2010) Rodryg Ramlau et al.   Journal of Thoracic Oncology

Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients

(2010) Susanne M Rittig et al.   MOLECULAR THERAPY

MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition

(2010) L D Roy et al.   ONCOGENE

MUC1-C Oncoprotein Functions as a Direct Activator of the Nuclear Factor- B p65 Transcription Factor

(2009) R. Ahmad et al.   CANCER RESEARCH

Tumor Burden Influences Cytotoxic T Cell Development in Metastatic Breast Cancer Patients—A Phase I/II Study

(2009) Stephen E. Wright et al.   IMMUNOLOGICAL INVESTIGATIONS

Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer

(2009) Ann Willman Silk et al.   MOLECULAR IMMUNOLOGY

Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer

(2009) N Khodarev et al.   ONCOGENE

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

(2008) J. L. Gulley et al.   CLINICAL CANCER RESEARCH

Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

(2008) Angèle L.M. Oei et al.   INTERNATIONAL JOURNAL OF CANCER

Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti‐MUC1 antibody immune selection

(2008) Juan Carlos Varela et al.   INTERNATIONAL JOURNAL OF CANCER

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

(2008) R. Dreicer et al.   INVESTIGATIONAL NEW DRUGS